Associate Editor: O. BinahPharmacological and non-pharmacological management of the congenital long QT syndrome: The rationale
Introduction
The congenital long QT syndrome (LQTS) is a relatively uncommon but important clinical disorder of genetic origin. Since 1975 (Schwartz et al., 1975), under the unifying name of "Long QT Syndrome" it includes two hereditary variants. The Jervell and Lange-Nielsen syndrome (J–LN) is associated with deafness (Jervell and Lange-Nielsen, 1957, Schwartz et al., 2006) and the Romano–Ward syndrome (R–W) is not (Romano et al., 1963, Ward, 1964).
The interest for LQTS has progressively increased, reaching an almost exponential growth during the last 15 years. The reasons are multiple, including two which are not novel. One is represented by the dramatic manifestations of the disease, namely syncopal episodes which often result in cardiac arrest and sudden death and usually occur in conditions of either physical or emotional stress in otherwise healthy young individuals, mostly children and teenagers. Another is that, while LQTS is a disease with a very high mortality rate among untreated patients, very effective therapies are available; this makes unacceptable and inexcusable the existence of symptomatic and undiagnosed or misdiagnosed patients. Since 1995 the identification of several genes responsible for LQTS, and moreover the realization that so far most of them encode ion channels, has provided a new stimulus for clinical cardiologists and basic scientists. The impressive correlation between specific mutations and critical alterations in the ionic control of ventricular repolarization makes this syndrome a unique paradigm which allows to correlate genotype and phenotype, thus providing a direct bridge between molecular biology and clinical cardiology in the area of sudden cardiac death.
Here, I will focus primarily on therapy. As generalities go, details on clinical manifestations can be found in a recent review (Schwartz & Crotti, 2009), the prevalence of LQTS is close to 1/2000 live births based on a prospective ECG study complemented by molecular screening in 44,000 infants (Schwartz et al., 2009a), and even though 12 LQTS genes have been identified the most important remain the first 3 identified which encode the IKs, the IKr, and the INa current (Schwartz and Crotti, 2009, Schwartz, in press).
Section snippets
Management and therapy for long QT syndrome
The cardinal aspects of LQTS therapy and management are essentially four: the two types of antiadrenergic interventions (β-blockers and left cardiac sympathetic denervation, LCSD), the implantable cardioverter defibrillator (ICD), and gene-specific management, which is still in its infancy.
Overview on therapy
The clear data available, and decades of clinical experience, dictate the therapeutic approach to the patient affected by LQTS who already has had a syncopal episode. Treatment should always begin with β-blockers, unless there are valid contraindications. If the patient has one more syncope despite full dose β-blockade, LCSD should be performed without hesitation and ICD implant should be considered with the final decision being based on the individual patient characteristics (age, sex,
Acknowledgments
This work was supported by National Institutes of Health grant HL-68880 and by the Telethon Italy grants GGP07016 and GGP09247. I am grateful Pinuccia De Tomasi for expert editorial support.
References (34)
- et al.
Video-assisted thorascopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias
Ann Thorac Surg
(2008) - et al.
Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery
Heart Rhythm
(2009) - et al.
Long QT syndrome in children in the era of implantable defibrillators
J Am Coll Cardiol
(2007) - et al.
Congenital deaf-mutism, functional heart disease with prolongation of the Q–T interval, and sudden death
Am Heart J
(1957) - et al.
Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias. The surgical supraclavicular approach to cervico-thoracic sympathectomy
Heart Rhythm
(2010) Cutting nerves and saving lives
Heart Rhythm
(2009)Efficacy of left cardiac sympathetic denervation has an unforeseen side effect: medicolegal complications
Heart Rhythm
(2010)- et al.
The long Q–T syndrome
Am Heart J
(1975) - et al.
Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold
Am J Cardiol
(1976) - et al.
Effects of unilateral stellate ganglion blockade on the arrhythmias associated with coronary occlusion
Am Heart J
(1976)
All LQT3 patients need an ICD. True or false?
Heart Rhythm
Molecular mechanism for an inherited cardiac arrhythmia
Nature
Effectiveness and limitations of β-blocker therapy in congenital long-QT syndrome
Circulation
Association of long QT syndrome loci and cardiac events among patients treated with β-blockers
JAMA
Aritmie cardiache rare dell'età pediatrica
Clin Pediatr
The rationale and the role of left stellectomy for the prevention of malignant arrhythmias
Ann NY Acad Sci
The congenital long QT syndromes from genotype to phenotype: clinical implications
J Intern Med
Cited by (25)
Strategies for prevention and management of QT interval prolongation and torsades de pointes
2022, Torsades de PointesDevice Therapy in the Setting of Long QT Syndrome
2015, Cardiac Electrophysiology ClinicsCitation Excerpt :To prevent Horner syndrome, some surgeons perform a high thoracic left sympathectomy in which the cephalic portion of the left stellate ganglion is left intact. Surgery is performed via a small left subclavicular incision with an extrapleural approach, taking an average of 35 to 40 minutes.5 At some centers, LCSD can be safely performed via a minimally invasive video-assisted thoracoscopic approach.35–37
Beta-blockers in the treatment of congenital long QT syndrome: Is one beta-blocker superior to another?
2014, Journal of the American College of CardiologyThe Dead-in-bed syndrome: Uncommon, or underestimated?
2013, Medecine des Maladies MetaboliquesThinking more before deciding to implant an ICD in LQT3 patients
2012, International Journal of CardiologyCarvedilol, a Non-Selective β-with α1-Blocker is Effective in Long QT Syndrome Type 2
2011, Journal of Arrhythmia